Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants
Evidence-Based Medicine, 10/26/09
Marlow N – Given before anticipated preterm birth, maternal magnesium sulphate prevents cerebral palsy in preterm infants.
Methods- Cochrane Pregnancy and Childbirth Group’s Trials Register (which contains results of searches of Cochrane Central Register of Controlled Trials, Medline, 30 journals, and major conference proceedings) was searched in August 2008 for randomised controlled trials (RCTs). 5 articles describing 6 RCTs (n = 6145 babies) met the selection criteria; in 4 RCTs, neuroprotection of the fetus was the primary objective of the trial.
- Included studies compared magnesium sulphate (administered intravenously, intramuscularly, or orally) with placebo, no treatment, or an alternate treatment (control) as a neuroprotective agent for the fetus when given to women at risk of preterm delivery.
- Studies in which the primary aim was other than fetal neuroprotection (eg, treatment of pre–eclampsia or preterm labour) were included if long–term infant neurological outcomes were reported.
- Outcomes were fetal/infant death, cerebral palsy, neurological impairment, and maternal side effects (such as nausea, vomiting, headache, palpitations, and flushing). Infants were evaluated at 18–24 months of age (corrected for prematurity) by blinded outcome assessors.
- Antenatal magnesium sulphate reduced risk of cerebral palsy and substantial gross motor dysfunction but not fetal/infant death.
- Groups did not differ for neurological impairment, blindness, deafness, developmental delay or intellectual impairment, or major neurological disability.
- Women in the magnesium sulphate group were 3 times more likely than those in the placebo group to discontinue treatment because of side effects.
Related Articles
Infants Born Preterm Exhibit Different Patterns of Center-of-Pressure Movement Than Infants Born at Full Term
Physical Therapy, 11/12/09
Relevance Score: 80%
Intraventricular Hemorrhage in Premature Infants: Mechanism of Disease
Pediatric Research, 10/12/09
Relevance Score: 80%
Academic, Social, and Behavioral Outcomes at Age 12 of Infants Born Preterm
Western Journal of Nursing Research, 11/04/09
Relevance Score: 79%
An Evidentiary Review Regarding the Use of Chronological and Adjusted Age in the Assessment of Preterm Infants
Journal for Specialists in Pediatric Nursing, 11/03/09
Relevance Score: 79%
Determinants of Ambulation in Children With Spastic Quadriplegic Cerebral Palsy: A Population-Based Study
Journal of Child Neurology, 10/20/09
Relevance Score: 79%
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization
Current Medical Research and Opinion, 11/25/09
Anti-relapse medications: Preclinical models for drug addiction treatment
Pharmacology & Therapeutics, 11/25/09
Glibenclamide-related excess in total and cardiovascular mortality risks: Data from large Ukrainian observational cohort study
Diabetes Research and Clinical Practice, 11/25/09
Sponsor
Article Search
Sponsor


See Latest Articles


